Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.

Kotani N, Ishiura Y, Yamashita R, Ohnishi T, Honke K.

J Biol Chem. 2012 Oct 26;287(44):37109-18. doi: 10.1074/jbc.M112.404178. Epub 2012 Aug 29.

2.

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.

Stel AJ, Ten Cate B, Jacobs S, Kok JW, Spierings DC, Dondorff M, Helfrich W, Kluin-Nelemans HC, de Leij LF, Withoff S, Kroesen BJ.

J Immunol. 2007 Feb 15;178(4):2287-95.

3.

Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.

Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E, Galun E, Avigdor A, Eizenberg O, Peled A, Nagler A.

Clin Cancer Res. 2013 Jul 1;19(13):3495-507. doi: 10.1158/1078-0432.CCR-12-3015. Epub 2013 May 1.

4.

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains.

Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Müller S, Jaffrézou JP, Laurent G.

Blood. 2004 Aug 15;104(4):1166-73. Epub 2004 May 4.

5.

Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.

Vega MI, Martínez-Paniagua M, Huerta-Yepez S, González-Bonilla C, Uematsu N, Bonavida B.

Int J Oncol. 2009 Dec;35(6):1289-96.

PMID:
19885551
6.

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Shan D, Ledbetter JA, Press OW.

Cancer Immunol Immunother. 2000 Mar;48(12):673-83.

PMID:
10752475
7.

TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.

Kawabata KC, Ehata S, Komuro A, Takeuchi K, Miyazono K.

Oncogene. 2013 Apr 18;32(16):2096-106. doi: 10.1038/onc.2012.219. Epub 2012 Jun 4.

PMID:
22665052
8.

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.

Oliveras-Ferraros C, Cufí S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, Bosch-Barrera J, Brunet J, Menendez JA.

Br J Cancer. 2012 Apr 10;106(8):1406-14. doi: 10.1038/bjc.2012.103.

9.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A.

J Clin Invest. 2009 May;119(5):1216-29. doi: 10.1172/JCI38017. Epub 2009 Apr 20.

10.

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.

Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW, Wasik M, Warzocha K, Sinski M, Gaciong Z, Jakobisiak M, Parren PW, Golab J.

PLoS Med. 2008 Mar 25;5(3):e64. doi: 10.1371/journal.pmed.0050064.

11.

FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.

Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J.

Cancer Res. 2012 Nov 15;72(22):5843-55. doi: 10.1158/0008-5472.CAN-12-1329. Epub 2012 Sep 26.

12.

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.

Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y.

Leukemia. 2010 Oct;24(10):1760-8. doi: 10.1038/leu.2010.157. Epub 2010 Aug 5.

PMID:
20686505
14.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC.

Haematologica. 2010 Dec;95(12):2063-71. doi: 10.3324/haematol.2010.025783. Epub 2010 Sep 17.

15.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
16.

Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.

Semac I, Palomba C, Kulangara K, Klages N, van Echten-Deckert G, Borisch B, Hoessli DC.

Cancer Res. 2003 Jan 15;63(2):534-40.

17.

MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.

Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K, Okada M.

Oncogene. 2011 Aug 11;30(32):3489-501. doi: 10.1038/onc.2011.63. Epub 2011 Mar 7.

PMID:
21383697
18.

Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms.

Wojciechowski W, Li H, Marshall S, Dell'Agnola C, Espinoza-Delgado I.

J Immunol. 2005 Jun 15;174(12):7859-68.

19.

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.

Al-Zoobi L, Salti S, Colavecchio A, Jundi M, Nadiri A, Hassan GS, El-Gabalawy H, Mourad W.

Int Immunol. 2014 Aug;26(8):451-65. doi: 10.1093/intimm/dxu046. Epub 2014 May 15.

PMID:
24894009
20.

FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.

Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM.

Clin Cancer Res. 2011 Jul 1;17(13):4389-99. doi: 10.1158/1078-0432.CCR-10-2772. Epub 2011 Apr 26.

Supplemental Content

Support Center